BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 19477032)

  • 1. Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer.
    Usuda J; Tsunoda Y; Ichinose S; Ishizumi T; Ohtani K; Maehara S; Ono S; Tsutsui H; Ohira T; Okunaka T; Furukawa K; Sugimoto Y; Kato H; Ikeda N
    Lung Cancer; 2010 Feb; 67(2):198-204. PubMed ID: 19477032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular determinants of photodynamic therapy for lung cancers.
    Usuda J; Ichinose S; Ishizumi T; Ohtani K; Inoue T; Maehara S; Imai K; Shima K; Ohira T; Kato H; Ikeda N
    Lasers Surg Med; 2011 Sep; 43(7):591-9. PubMed ID: 22057486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strongly amphiphilic photosensitizers are not substrates of the cancer stem cell marker ABCG2 and provides specific and efficient light-triggered drug delivery of an EGFR-targeted cytotoxic drug.
    Selbo PK; Weyergang A; Eng MS; Bostad M; Mælandsmo GM; Høgset A; Berg K
    J Control Release; 2012 Apr; 159(2):197-203. PubMed ID: 22349185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ABCG2 transporter is a key molecular determinant of the efficacy of sonodynamic therapy with Photofrin in glioma stem-like cells.
    Xu ZY; Wang K; Li XQ; Chen S; Deng JM; Cheng Y; Wang ZG
    Ultrasonics; 2013 Jan; 53(1):232-8. PubMed ID: 22771084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways >1.0 cm in diameter.
    Usuda J; Ichinose S; Ishizumi T; Hayashi H; Ohtani K; Maehara S; Ono S; Honda H; Kajiwara N; Uchida O; Tsutsui H; Ohira T; Kato H; Ikeda N
    Clin Cancer Res; 2010 Apr; 16(7):2198-204. PubMed ID: 20332318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response.
    Ferrario A; Rucker N; Wong S; Luna M; Gomer CJ
    Cancer Res; 2007 May; 67(10):4989-95. PubMed ID: 17510430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression.
    Jung KA; Choi BH; Kwak MK
    Mol Pharmacol; 2015; 87(3):465-76. PubMed ID: 25534417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2.
    Liu W; Baer MR; Bowman MJ; Pera P; Zheng X; Morgan J; Pandey RA; Oseroff AR
    Clin Cancer Res; 2007 Apr; 13(8):2463-70. PubMed ID: 17438106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells.
    Jendzelovský R; Mikes J; Koval' J; Soucek K; Procházková J; Kello M; Sacková V; Hofmanová J; Kozubík A; Fedorocko P
    Photochem Photobiol Sci; 2009 Dec; 8(12):1716-23. PubMed ID: 20024169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
    Peng Q; Warloe T; Moan J; Godal A; Apricena F; Giercksky KE; Nesland JM
    Cancer Res; 2001 Aug; 61(15):5824-32. PubMed ID: 11479222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and functional analyses of breast cancer resistance protein in lung cancer.
    Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
    Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sensitivity of glioma cells to pyropheophorbide-αmethyl ester-mediated photodynamic therapy is enhanced by inhibiting ABCG2.
    Pan L; Lin H; Tian S; Bai D; Kong Y; Yu L
    Lasers Surg Med; 2017 Sep; 49(7):719-726. PubMed ID: 28370217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation and photodynamic activity of chlorin e6 in cisplatin-resistant human lung cancer cells.
    Horibe S; Nagai J; Yumoto R; Tawa R; Takano M
    J Pharm Sci; 2011 Jul; 100(7):3010-7. PubMed ID: 21274848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of ephrin-A1 on resistance to Photofrin-mediated photodynamic therapy in esophageal squamous cell carcinoma cells.
    Yang PW; Chiang TH; Hsieh CY; Huang YC; Wong LF; Hung MC; Tsai JC; Lee JM
    Lasers Med Sci; 2015 Dec; 30(9):2353-61. PubMed ID: 26450615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced efficacy of photodynamic therapy by inhibiting ABCG2 in colon cancers.
    Kim JH; Park JM; Roh YJ; Kim IW; Hasan T; Choi MG
    BMC Cancer; 2015 Jul; 15():504. PubMed ID: 26149077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer resistance protein is the enemy of hypericin accumulation and toxicity of hypericin-mediated photodynamic therapy.
    Jendželovský R; Jendželovská Z; Kuchárová B; Fedoročko P
    Biomed Pharmacother; 2019 Jan; 109():2173-2181. PubMed ID: 30551474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pivotal roles of peptide transporter PEPT1 and ATP-binding cassette (ABC) transporter ABCG2 in 5-aminolevulinic acid (ALA)-based photocytotoxicity of gastric cancer cells in vitro.
    Hagiya Y; Endo Y; Yonemura Y; Takahashi K; Ishizuka M; Abe F; Tanaka T; Okura I; Nakajima M; Ishikawa T; Ogura S
    Photodiagnosis Photodyn Ther; 2012 Sep; 9(3):204-14. PubMed ID: 22959800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
    Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
    Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Porphyrin-lipid assemblies and nanovesicles overcome ABC transporter-mediated photodynamic therapy resistance in cancer cells.
    Baglo Y; Liang BJ; Robey RW; Ambudkar SV; Gottesman MM; Huang HC
    Cancer Lett; 2019 Aug; 457():110-118. PubMed ID: 31071369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.